Denali Therapeutics Inc. — Director's Dealing 2017

Dec 12, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2017-12-12

Reporting Person: Schenkein David P (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-12	Common Stock	C	105225	—	Acquired	105225	Indirect
2017-12-12	Common Stock	C	19774	—	Acquired	19774	Indirect
2017-12-12	Common Stock	C	105225	—	Acquired	105225	Indirect
2017-12-12	Common Stock	C	19774	—	Acquired	19774	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-12	Series A-1 Preferred Stock	$	C	105225	Disposed		Common Stock (105225)	Indirect
2017-12-12	Series A-1 Preferred Stock	$	C	19774	Disposed		Common Stock (19774)	Indirect
2017-12-12	Series A-1 Preferred Stock	$	C	105225	Disposed		Common Stock (105225)	Indirect
2017-12-12	Series A-1 Preferred Stock	$	C	19774	Disposed		Common Stock (19774)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	75000	Direct

Footnotes

F1: The Series A-1 Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2: The shares are held of record by the David P. Schenkein 2015 Denali Qualified Annuity Trust, for which the Reporting Person serves as a trustee.

F3: The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee.

F4: The shares are held of record by the Amy P. Schenkein 2015 Denali Qualified Annuity Trust, for which the Reporting Person serves as a trustee.

F5: The shares are held of record by the Amy P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee.